Credit: Genentech. Susvimo is indicated for intravitreal use via the Susvimo ocular implant. For patients with diabetic retinopathy, refills of Susvimo are administered every 36 weeks (approximately 9 ...

Patients with diabetes face a host of potential health problems as they work to manage the chronic disease. Still, one concern that seems to weigh heavily is the risk of losing their sight through a ...

An injection of 6 mg of intravitreal brolucizumab was at least as effective as — and potentially superior to — panretinal laser photocoagulation in preserving vision in patients with proliferative ...

Please provide your email address to receive an email when new articles are posted on . The approval is based on positive 1-year data from the phase 3 Pavilion study. This is Susvimo’s third ...

For prevention of diabetic retinopathy (DR) incidence or progression, the American Academy of Ophthalmology Preferred Practice Pattern (AAO PPP) and the American Diabetes Association Standards of Care ...

Jose Martinez, MD, and Robert Wong, MD, review treatment plans for patients with mild, moderate, and more severe forms of diabetic retinopathy. Transcript Jose Martinez, MD: For patients who present ...

Maria Grant, MD, along with her team at the UAB Heersink School of Medicine Department of Ophthalmology and Visual Sciences teamed up with researchers from the University of Florida College of ...

People with diabetes may develop diabetic retinopathy, a condition in which elevated blood glucose damages blood vessels in the retina. This can lead to visual symptoms like blurriness, distortion, ...

This story is part of a series on the current progression in Regenerative Medicine. This piece is part of a series dedicated to the eye and improvements in restoring vision. This piece also marks part ...